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Key points
TSOACs are associated with less major bleeding, fatal bleeding, clinically relevant non-major bleeding and total bleeding.
The meta-analysis do not show increasing risk of major gastrointestinal bleeding in patients who received TSOACs compared to warfarin.
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Introduction
Vitamin K antagonists (VKAs) have been the standard of care for thromboembolic diseases including venous thromboembolism (VTE) and stroke from systemic embolism due to atrial fibrillation (AF). VKAs provide an estimated 95% relative risk reduction in recurrent VTE compared with the placebo 1 . In non-valvular AF, VKAs are highly effective for the prevention of stroke with a relative reduction of 65% compared with placebo 2 . While effective, the major obstacle to the use of VKAs is bleeding complications. The rate of major bleeding among long-term users of VKAs is 1.5-5.2% per year. The mortality rate from major bleeding events exceeds 13% 3, 4 . Intracranial bleeding is the most devastating complication of VKA use, comprising approximately 8.7% of all major bleeding episodes and resulting in a 46-55% mortality rate 5, 6 .
Apart from hemorrhage, VKAs have several limitations including the need for laboratory monitoring, dietary and drug interactions, a slow onset of action and a narrow therapeutic window. Target-specific anticoagulants (TSOACs), which directly inhibit coagulation factor Xa (rivaroxaban, apixaban, edoxaban, betrixaban, darexaban) or thrombin (dabigatran) have been developed to overcome these limitations.
Recent clinical trials demonstrated that TSOACs were non-inferior to VKAs for the treatment of acute VTE [7] [8] [9] and extended use of TSOACs reduced the risk of recurrent VTE when compared to placebo 10, 11 . Furthermore TSOACs demonstrated comparable or better efficacy to VKAs with respect to the prevention of stroke or systemic embolism in patients with AF 12-15 .
Bleeding still remains a major concern of TSOACs. The risk of bleeding from TSOACs is uncertain and reported rates are conflicting and heterogeneous. Despite some clinical trials reporting that TSOACs are associated with lower risks of major bleeding 8, 13, 15 , other studies suggest that the bleeding profiles are similar to that of VKAs 14 , 16 . Notably, the real-world data
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From suggests the observed bleeding risk is lower than that experienced using warfarin 17 . Although systematic reviews on the efficacy and safety of TSOACs have been published [18] [19] [20] , there are no systematic reviews examining the bleeding complications across various indications of TSOACs. We therefore performed a systematic review and meta-analysis to examine the impact of bleeding complications of TSOACs compared with the VKAs in patients with VTE or AF.
Methods

Selection Criteria
Studies were included if they were phase III randomized controlled trials ( VKAs and reported the rate of bleeding between the groups. Studies that used heparin or lowmolecular weight heparin (LMWH) followed by VKAs were also included. There were no limitations based on blinding, language or publication status. We included unpublished trials if the methodology and data met our eligibility criteria. We excluded studies of TSOACs used for primary VTE prophylaxis or other indications (e.g. mechanical heart valves, acute coronary syndrome, treatment of thrombus in left atrial appendage). We excluded ximelagatran as this drug has been withdrawn from the market. We excluded studies that used non-VKAs as the comparator (e.g., aspirin, heparin, placebo). Co-intervention with anti-platelet agent (aspirin or clopidogrel) was allowed. The primary outcome of the review was major bleeding as defined by the International Society on Thrombosis and Haemostasis (ISTH) 21 or as defined by the studies. The secondary outcomes included fatal bleeding, intracranial bleeding, clinically
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Data Sources and Searches
The electronic searches were performed in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) databases. The search strategy for MEDLINE is available in supplemental table 1. The search strategy was slightly modified for the other databases. The articles published from inception to January 2014 were eligible for inclusion in this review. 
Study Selection
Two reviewers (C.C. and T.I.) performed the study selection independently based on the defined inclusion and exclusion criteria. Disagreements were resolved through discussion or through a third reviewer (W.L.). The kappa statistic was used to assess the agreement between reviewers for study selection. A kappa value of 0.75 or more indicates excellent agreement 23 .
For trials which reported results in more than one publication, we extracted data from the most complete publication and used the other publications to clarify the data. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement for reporting of systematic reviews and meta-analyses of randomized clinical trials was followed 22 .
Data Extraction
Two reviewers (C.C. and T.I.) performed data extraction independently using standardized data extraction sheets. Discrepancies between the reviewers were resolved by consensus or through a third reviewer (W.L). The following data were extracted from the included trials: study design, year of publication, source of funding, population characteristics (number of patients, mean or median age and sex), therapeutic indication (VTE or AF), interventions (type of TSOAC and duration of treatment), treatment in the control arm, cointerventions, mean time in therapeutic range (TTR) during VKA therapy and relevant information related to bleeding (major bleeding [as per ISTH or defined by the study], fatal bleeding, intracranial hemorrhage, clinically relevant non-major bleeding, total bleeding, gastrointestinal bleeding).
Quality Assessment
In order to ascertain the validity of eligible randomized trails, two reviewers (C.C. and T.I.) independently assessed study quality using the methods specified in the Cochrane 
Subgroup analyses
We performed two pre-specified a priori subgroup analyses, namely the indication for anticoagulation (AF vs VTE) and types of TSOAC (dabigatran, rivaroxaban, apixaban and edoxaban).
Sensitivity analyses
We performed three sensitivity analyses. The first was based on the quality of the studies to demonstrate the robustness of the effect estimates when studies with a high risk of bias were excluded. Studies were considered low quality if there was a lack of blinding or if there was a 'No' response in the Risk of Bias Assessment table. We also repeated our analyses based on the duration of treatment (≤ 12 months and > 12 months). Last, since we used the random-effects model in the primary analyses, we performed an analysis using a fixed-effects model.
Results
Study identification and selection
Using electronic searches in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials, 7937 citations were obtained. An additional 28 studies were identified from hand searching conference proceedings (supplemental Figure 1) . 
Baseline characteristics
The main characteristics of the included studies are summarized in Table 1 and the baseline characteristics of the patients are shown in Table 2 . Indications for anticoagulation were VTE (7 trials) and for stroke and systemic embolism prevention from AF (5 trials). The patients were treated for 1.6-2.0 years in most of the AF trials, whereas patients in the VTE trials were treated for 3-12 months. All of the 12 studies were sponsored by pharmaceutical companies. The mean (or median) age of participants ranged from 70-73 years (AF) and 54-57 years (VTE). TTR in patients receiving VKAs ranged from 55% to 65%.
Study quality
The risk of bias assessment is demonstrated in supplemental Figure 2 . The method used to generate the random sequence and allocation concealment was inadequately reported in 1 study 28 . The EINSTEIN DVT 16 , EINSTEIN PE 29 and RE-LY 12 trials were not blinded.
TSOACs are typically dose reduced in patients with renal impairment, which may also have contributed to bias in the bleeding outcomes. Visual inspection of funnel plots for all outcomes suggested no evidence of publication bias supplemental Figure 3 .
Major bleeding
In the 12 RCTs comparing TSOACs with VKAs with a target INR of 2-3, major bleeding as defined by the studies or using ISTH criteria 21 occurred in 2320 of 57850 (4%) of the patients treated with TSOACs and in 2081 of 44757 (4.64%) of the patients treated with
VKAs. The pooled RR for major bleeding was 0.72 (95% CI, 0.62-0.85), P<0.01, I 2 = 78%.
( Figure 1 ). The absolute risk difference for major bleeding was -0.64%, with a NNT of 156
using TSOACs compared to VKAs. The sensitivity analysis using a fixed-effects model had no effect on our results supplemental Figure 4 . Figure 5 ). Analysis using a fixed-effects model resulted in all TSOACs except rivaroxaban demonstrating statistically significant reductions in major bleeding (data not shown). 2 =16%) but not in patients with AF (supplemental Figure 7) .
Fatal bleeding
The subgroup analysis according to type of TSOACs provided similar results to the primary analysis.
Sensitivity Analyses
Sensitivity analyses evaluating only the high-quality studies (excluding studies with lack of blinding), did not change the findings from the primary analysis for all outcomes Our finding is consistent with the previous systematic reviews 19, 34, 38 that TSOACs are associated with lower major bleeding. We observed statistically significant heterogeneity for major bleeding (I 2 =78%) and clinically relevant non major bleeding (I 2 =89%). The observed heterogeneity can potentially be explained by the different TSOACs included in this review.
The subgroup analyses demonstrated that the risk reduction of bleeding from trials evaluating rivaroxaban were not significantly different compared to VKAs. One potential explanation is that the results of trials evaluating rivaroxaban are mainly driven by ROCKET AF 14 and J-ROCKET AF 28 , these two trials enrolled atrial fibrillation patients with relatively high CHADS2 score that are known to place such patients at high risk of bleeding 40 . Other heterogeneity might be explained by differences in baseline patient characteristics in the AF and VTE trials that we included in this review. Therefore, the pooled estimates of these 14 . One of the mechanism of TSOAC-associated gastrointestinal bleeding might be explained from the active drugs remaining in the gastrointestinal tract and precipitating bleeding from vulnerable lesions 42 . The previous systematic reviews reported that TSOACs were associated with significantly increased risk of gastrointestinal bleeding compared to standard care (warfarin, LMWH, LMWH followed by warfarin or placebo) 30, 43 . However, our meta-analysis did not demonstrate that TSOACs increase the rate of major gastrointestinal bleeding (RR 0.94 [95% CI 0.88-1.34], P = 0.62).
The discrepancy of this finding might be explained form the difference of the population and The strengths of this review include the rigorous methodological approach and large number of included patients. We included 12 large RCTs evaluating 4 TSOACs (dabigatran, rivaroxaban, apixaban and edoxaban) across 2 major indications. We included more than 100000 patients in the meta-analysis and consequently have the statistical power to detect differences in uncommon outcomes including fatal bleeding and intracranial bleeding. In contrast to previous studies 18, 34, 35, 38 , we only included studies using VKAs as the comparator to generate more precise estimates of risk.
There are several limitations to this study. First, there were differences in the study population, type of TSOACs evaluated and duration of treatment that may have contributed to the heterogeneity observed in the results. However, our sensitivity analyses did not demonstrate different findings for most of the outcomes. Second, because this was a study-level metaanalysis, we were unable to compare the outcome in patient subgroups by use of anti-platelet agents. In an analysis of the RE-LY data, the concomitant use of single or dual antiplatelet agents was associated with an increased risk of major bleeding 44 . 
Conclusions
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